Publications
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. Future oncology (London, England). 2023. PMID: 37916267
Tempero M. Giving Thanks. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37935094
Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. The Lancet. Oncology. 2023. PMID: 37922930
Patel K, Hsu KY, Lou K, Soni K, Lee YJ, Mulvey CK, Baik AH. Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report. Cardio-oncology (London, England). 2023. PMID: 37908018
Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. Structural surfaceomics reveals an AML-specific conformation of integrin ß2 as a CAR T cellular therapy target. Nature cancer. 2023. PMID: 37904046
Umashankar S, Basu A, Esserman L, Van't Veer L, Melisko ME. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients. Cancer medicine. 2023. PMID: 37902219
Lee RH, Truong A, Wu X, Kang H, Algazi AP, El-Sayed IH, George JR, Heaton CM, Ryan WR, Ha PK, Wai KC. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab. Head & neck. 2023. PMID: 37897202
Logan A. Innovating Simpler and Less Toxic Frontline Management for Adults With ALL. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023. PMID: 37883737
Allegakoen DV, Kwong K, Morales J, Bivona TG, Sabnis AJ. The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression. bioRxiv : the preprint server for biology. 2023. PMID: 37961102
Record H, Clelland E, Rothschild HT, Kaur M, Chien AJ, Melisko M, Rugo HS, Mujir F, Huppert L, Mukhtar RA. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer. NPJ breast cancer. 2023. PMID: 37884561
Siwik CJ, Jhaveri K, Cohen JA, Barulich M, Chang A, Levin AO, Goyal NG, Melisko M, Chesney MA, Shumay D. Survivorship wellness: a multidisciplinary group program for cancer survivors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2023. PMID: 37882860
Razak ARA, Wang HM, Chang JY, Ahn MJ, Munster P, Blumenschein G, Solomon B, Lim DW, Hong RL, Pfister D, Saba NF, Lee SH, van Herpen C, Quadt C, Bootle D, Blumenstein L, Demanse D, Delord JP. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted oncology. 2023. PMID: 37875771
Cai SF, Huang Y, Lance JR, Mao HCC, Dunbar A, McNulty S, Druley TE, Li Y, Baer MR, Stock W, Kovacsovics T, Blum W, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben AB, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood advances. 2023. PMID: 37871309
Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN. A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models. Research square. 2023. PMID: 37961240
Hamadani M, Spira AI, Zhou X, Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical Outcomes of Older and Younger Patients Treated with Loncastuximab Tesirine in the LOTIS-2 Clinical Trial. Blood advances. 2023. PMID: 37871303
Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshna KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH. PET/CT-biomarkers enable risk stratification of patients with relapsed/refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. PMID: 37855688
Sam R, Zhang L, Tuot DS, Chaudhry R. The Decrease in Serum Total Cholesterol and Low-Density Lipoprotein (LDL) Concentrations With the Initiation of Hemodialysis Despite a Concomitant Increase in Serum Albumin Concentrations. Cureus. 2023. PMID: 38022186
Michael LaPelusa, Hiba Khan, Curtiland Deville, Samuel L Washington, Hala T Borno. Advancing Equity in Oncology: Innovative Approaches and Robust Frameworks to Address Cancer Health Disparities. International Journal of Cancer Care and Delivery. 2023. PMID:
Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, Lopes GL, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP, COVID-19 and Cancer Consortium. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study. eLife. 2023. PMID: 37846664
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. International journal of cancer. 2023. PMID: 37831416